Patents by Inventor Lucy Rutten
Lucy Rutten has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230374078Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.Type: ApplicationFiled: June 28, 2023Publication date: November 23, 2023Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Nika Mindy STROKAPPE, Daphné TRUAN
-
Patent number: 11820796Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.Type: GrantFiled: June 8, 2022Date of Patent: November 21, 2023Assignee: Janssen Vaccines & Prevention B.V.Inventors: Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes Petrus Maria Langedijk
-
Publication number: 20230310573Abstract: The present invention relates to vaccine composition comprising an immunologically effective amount of a viral fusion protein antigen, such as an RSV pre-fusion F protein, and a stabilizing amount of an antiviral compound, and to methods for preparing such vaccine compositions.Type: ApplicationFiled: April 1, 2021Publication date: October 5, 2023Inventors: Tina RITSCHEL, Richard VOORZAAT, Lucy RUTTEN, Mandy Antonia Catharina JONGENEELEN, Tim Hugo Maria JONCKERS, Dirk André Emmy ROYMANS, Johannes Petrus Maria LANGEDIJK
-
Publication number: 20230302119Abstract: The present invention provides stabilized recombinant pre-fusion SARS CoV0-2 S proteins, nucleic acids molecules encoding the SARS CoV-2 S proteins and uses thereof.Type: ApplicationFiled: July 5, 2021Publication date: September 28, 2023Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Jaroslaw JURASZEK
-
Patent number: 11732010Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.Type: GrantFiled: February 22, 2021Date of Patent: August 22, 2023Assignee: Janssen Vaccines & Prevention B.V.Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Nika Mindy Strokappe, Daphné Truan
-
Patent number: 11603390Abstract: Filovirus glycoprotein mutations that stabilize the trimeric form of the glycoprotein are provided. The Filovirus glycoproteins have certain amino acid substitutions at specified positions in the glycoprotein sequence. The Filovirus glycoproteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to a Filovirus glycoprotein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the Filovirus glycoproteins, as well as compositions containing the Filovirus glycoproteins, nucleic acid, and vectors.Type: GrantFiled: August 13, 2019Date of Patent: March 14, 2023Assignee: JANSSEN VACCINES & PREVENTION B.V.Inventors: Johannes Langedijk, Lucy Rutten, Sven Blokland
-
Publication number: 20230075527Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).Type: ApplicationFiled: January 30, 2021Publication date: March 9, 2023Inventors: Dan H. BAROUCH, Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Theodorus Maria ZUIJDGEEST, An VANDEBOSCH, Mathieu Claude Michel LE GARS, Jerald C. SADOFF
-
Patent number: 11498944Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).Type: GrantFiled: January 30, 2021Date of Patent: November 15, 2022Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel Le Gars, Jerald C. Sadoff
-
Publication number: 20220315627Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.Type: ApplicationFiled: June 8, 2022Publication date: October 6, 2022Inventors: Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes Petrus Maria Langedijk
-
Publication number: 20220265813Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.Type: ApplicationFiled: February 22, 2022Publication date: August 25, 2022Inventors: Johannes Petrus Maria Langedijk, Jaroslaw Juraszek, Lucy Rutten
-
Patent number: 11384122Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).Type: GrantFiled: July 28, 2021Date of Patent: July 12, 2022Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Mark Johannes Gerardus Bakkers, Rinke Bos, Frank Wegmann, David Adrianus Theodorus Maria Zuijdgeest, Dan H. Barouch, An Vandebosch, Mathieu Claude Michel le Gars, Jerald C. Sadoff
-
Patent number: 11365222Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.Type: GrantFiled: August 13, 2020Date of Patent: June 21, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes P. M. Langedijk
-
Publication number: 20210388032Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).Type: ApplicationFiled: July 28, 2021Publication date: December 16, 2021Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Thedorus Maria ZUIJDGEEST, Dan H. BAROUCH, An VANDEBOSCH, Mathieu Claude Michel le GARS, Jerald C. SADOFF
-
Publication number: 20210346492Abstract: RNA replicons encoding coronavirus S proteins, in particular SARS-CoV-2 S proteins, are described. Also described are pharmaceutical compositions and uses of the RNA replicons.Type: ApplicationFiled: May 11, 2021Publication date: November 11, 2021Inventors: Jason DEHART, Christian MAINE, Brett Steven MARRO, Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Ronald VOGELS, Marijn VAN DER NEUT KOLFSCHOTEN, Aneesh VIJAYAN
-
Publication number: 20210347828Abstract: RNA replicons encoding stabilized recombinant pre-fusion SARS CoV-2 S proteins are described. Also described are pharmaceutical compositions and uses of the RNA replicons.Type: ApplicationFiled: May 11, 2021Publication date: November 11, 2021Inventors: Jason DEHART, Christian MAINE, Brett Steven MARRO, Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Ronald VOGELS, Marijn VAN DER NEUT KOLFSCHOTEN, Jaroslaw JURASZEK, Aneesh VIJAYAN
-
Publication number: 20210292371Abstract: Filovirus glycoprotein mutations that stabilize the trimeric form of the glycoprotein are provided. The Filovirus glycoproteins have certain amino acid substitutions at specified positions in the glycoprotein sequence. The Filovirus glycoproteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to a Filovirus glycoprotein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the Filovirus glycoproteins, as well as compositions containing the Filovirus glycoproteins, nucleic acid, and vectors.Type: ApplicationFiled: August 13, 2019Publication date: September 23, 2021Inventors: Johannes LANGEDIJK, Lucy RUTTEN, Sven BLOKLAND
-
Publication number: 20210246170Abstract: The invention relates to immunogenic compositions and vaccines containing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; also referred to as SARS-CoV-2)) protein or a polynucleotide encoding a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) protein and uses thereof. The invention also provides methods of treating and/or preventing a coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) infection by administering an immunogenic composition or vaccine to a subject (e.g., a human). The invention also provides methods of detecting and/or monitoring a protective anti-coronavirus (e.g., Wuhan coronavirus (2019-nCoV; SARS-CoV-2)) antibody response (e.g., anti-coronavirus antibody response, e.g., anti-2019-nCoV antibody response, e.g., anti-Spike antibody response, e.g., anti-Spike neutralizing antibody response).Type: ApplicationFiled: January 30, 2021Publication date: August 12, 2021Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Mark Johannes Gerardus BAKKERS, Rinke BOS, Frank WEGMANN, David Adrianus Theodorus Maria ZUIJDGEEST, Dan H. BAROUCH, An VANDEBOSCH, Mathieu Claude Michel le GARS, Jerald C. SADOFF
-
Publication number: 20210188918Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.Type: ApplicationFiled: February 22, 2021Publication date: June 24, 2021Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Nika Mindy STROKAPPE, Daphné TRUAN
-
Patent number: 10968254Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.Type: GrantFiled: July 19, 2018Date of Patent: April 6, 2021Assignee: Janssen Vaccines & Prevention B.V.Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Nika Mindy Strokappe, Daphné Truan
-
Publication number: 20200369731Abstract: Human immunodeficiency virus (HIV) envelope proteins having mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins have certain amino acid substitutions at specified positions in the envelope protein sequence. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield as compared to an HIV envelope protein that does not have one or more of the indicated amino acid substitutions. Also provided are nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, nucleic acid, and vectors.Type: ApplicationFiled: August 13, 2020Publication date: November 26, 2020Inventors: Lucy Rutten, Daphné Truan, Nika Mindy Strokappe, Johannes P. M. Langedijk